

## Review Form 1.6

|                          |   |
|--------------------------|---|
| Journal Name:            | <a href="#">Journal of Pharmaceutical Research International</a>                      |
| Manuscript Number:       | Ms_JPRI_80491   |
| Title of the Manuscript: | <b>New Perspectives on Clopidogrel Resistance Systematic Review and Meta-analysis</b> |
| Type of the Article      |   |

### **General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

<https://www.journaljpri.com/index.php/JPRI/editorial-policy>

**Review Form 1.6****PART 1: Review Comments**

|                                     | <b>Reviewer's comment</b>   | <b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|-------------------------------------|---|--|
| <b>Compulsory</b> REVISION comments | The present analysis provides important information for decision-making in the clinic for the management of resistance events in patients to clopidogrel. However, the methodology did not mention the inclusion and exclusion criteria of the studies, nor the time window or language considered. In the presentation of the results, a table is used that summarises the main characteristics of the studies, but it does not mention how many studies were initially considered and which were discarded, nor the reason for keeping 14 studies. makes a description of the same information as text (I consider one of the two should be removed). The authors relate the presence of resistance to genetic polymorphisms, but nowhere in the document are these polymorphisms presented. In the recommendations, the authors recommend the use of other antiplatelet agents as an alternative, but this is not supported by the research carried out, so I believe that the authors should recommend carrying out studies on the effectiveness of these drugs in patients who present resistance to antiplatelet agents. clopidogrel, to determine if they are a valid alternative.<br>Finally, make some suggestions for some spelling and grammar corrections in the attached document. |  |
| <b>Minor</b> REVISION comments      | The present analysis provides important information for decision-making in the clinic for the management of resistance events in patients to clopidogrel. However, the methodology did not mention the inclusion and exclusion criteria of the studies, nor the time window or language considered. In the presentation of the results, a table is used that summarises the main characteristics of the studies, but it does not mention how many studies were initially considered and which were discarded, nor the reason for keeping 14 studies. makes a description of the same information as text (I consider one of the two should be removed). The authors relate the presence of resistance to genetic polymorphisms, but nowhere in the document are these polymorphisms presented. In the recommendations, the authors recommend the use of other antiplatelet agents as an alternative, but this is not supported by the research carried out, so I believe that the authors should recommend carrying out studies on the effectiveness of these drugs in patients who present resistance to antiplatelet agents. clopidogrel, to determine if they are a valid alternative.<br>Finally, make some suggestions for some spelling and grammar corrections in the attached document. |  |
| <b>Optional/General</b> comments    |   |  |

**PART 2:**

|   | <b>Reviewer's comment</b>  | <b>Author's comment</b> (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here) |
|---|--|--|
| <b>Are there ethical issues in this manuscript?</b> | <i>(If yes, Kindly please write down the ethical issues here in details)</i> |  |

**Reviewer Details:**

|                                  |  |
|----------------------------------|--|
| Name:                            | <b>Jhon Carlos Castaño Osorio</b>        |
| Department, University & Country | <b>Universidad del Quindío, Colombia</b> |